Small-molecule modulators of tumor necrosis factor signaling

Department of Drug Design and Pharmacology

Small-molecule modulators of tumor necrosis factor signaling

Research output: Contribution to journal › Review › Research › peer-review

Standard

Small-molecule modulators of tumor necrosis factor signaling. / Chédotal, Henri; Narayanan, Dilip; Povlsen, Katrine; Gotfredsen, Charlotte H.; Brambilla, Roberta; Gajhede, Michael; Bach, Anders; Clausen, Mads H.

In: Drug Discovery Today, Vol. 28, No. 6, 103575, 2023.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Chédotal, H, Narayanan, D, Povlsen, K, Gotfredsen, CH, Brambilla, R, Gajhede, M, Bach, A & Clausen, MH 2023, 'Small-molecule modulators of tumor necrosis factor signaling', Drug Discovery Today, vol. 28, no. 6, 103575. https://doi.org/10.1016/j.drudis.2023.103575

APA

Chédotal, H., Narayanan, D., Povlsen, K., Gotfredsen, C. H., Brambilla, R., Gajhede, M., Bach, A., & Clausen, M. H. (2023). Small-molecule modulators of tumor necrosis factor signaling. Drug Discovery Today, 28(6), [103575]. https://doi.org/10.1016/j.drudis.2023.103575

Vancouver

Chédotal H, Narayanan D, Povlsen K, Gotfredsen CH, Brambilla R, Gajhede M et al. Small-molecule modulators of tumor necrosis factor signaling. Drug Discovery Today. 2023;28(6). 103575. https://doi.org/10.1016/j.drudis.2023.103575

Author

Chédotal, Henri ; Narayanan, Dilip ; Povlsen, Katrine ; Gotfredsen, Charlotte H. ; Brambilla, Roberta ; Gajhede, Michael ; Bach, Anders ; Clausen, Mads H. / Small-molecule modulators of tumor necrosis factor signaling. In: Drug Discovery Today. 2023 ; Vol. 28, No. 6.

Bibtex

@article{0c7772f0d6e5422a8852032c535e3320,

title = "Small-molecule modulators of tumor necrosis factor signaling",

abstract = "Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.",

author = "Henri Ch{\'e}dotal and Dilip Narayanan and Katrine Povlsen and Gotfredsen, {Charlotte H.} and Roberta Brambilla and Michael Gajhede and Anders Bach and Clausen, {Mads H.}",

year = "2023",

doi = "10.1016/j.drudis.2023.103575",

language = "English",

volume = "28",

journal = "Drug Discovery Today: BIOSILICO",

issn = "1359-6446",

publisher = "Elsevier Ltd. * Trends Journals",

number = "6",

}

RIS

TY - JOUR

T1 - Small-molecule modulators of tumor necrosis factor signaling

AU - Chédotal, Henri

AU - Narayanan, Dilip

AU - Povlsen, Katrine

AU - Gotfredsen, Charlotte H.

AU - Brambilla, Roberta

AU - Gajhede, Michael

AU - Bach, Anders

AU - Clausen, Mads H.

PY - 2023

Y1 - 2023

N2 - Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.

AB - Tumor necrosis factor (TNF) is a pleiotropic cytokine with a major role in immune system homeostasis and is involved in many inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA), psoriasis, Alzheimer's disease (AD), and multiple sclerosis (MS). Thus, TNF and its receptors, TNFR1 and TNFR2, are relevant pharmacological targets. Biologics have been developed to block TNF-dependent signaling cascades, but they display serious side effects, and their pharmacological effectiveness decreases over time because of their immunogenicity. In this review, we present recent discoveries in small molecules targeting TNF and its receptors and discuss alternative strategies for modulating TNF signaling.

U2 - 10.1016/j.drudis.2023.103575

DO - 10.1016/j.drudis.2023.103575

M3 - Review

C2 - 37003513

VL - 28

JO - Drug Discovery Today: BIOSILICO

JF - Drug Discovery Today: BIOSILICO

SN - 1359-6446

IS - 6

M1 - 103575

ER -

ID: 341791263